The US patent, when granted, gives PainChek® exclusive rights to exclude others from making, using, selling or importing the invention for 20 years from the filing date in the US (17 February 2017).According to Philip Daffas, PainChek® CEO, the patent is the latest in a series of growth milestones for the company in 2019.“After working on this application since early 2017, our team is delighted with the United States Patent and Trademark Office (USPTO) grant. The PainChek® technology effectively gives a voice to people who can’t verbalise their pain and this patent will further expand our commercial efforts,” said Mr Daffas. ...... So 17 Februray 2037 ....
PCK Price at posting:
14.5¢ Sentiment: Buy Disclosure: Held
